Comparative Pharmacology
Head-to-head clinical analysis: PANMYCIN versus TETRAMED.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PANMYCIN versus TETRAMED.
PANMYCIN vs TETRAMED
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Tetracycline antibiotic that inhibits bacterial protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from attaching to the A site.
Tetracycline inhibits protein synthesis by binding to the 30S ribosomal subunit, preventing aminoacyl-tRNA from binding to the ribosome.
250-500 mg PO q6h or 500 mg to 1 g IV q6h; maximum 4 g/day
100 mg orally every 12 hours
None Documented
None Documented
Terminal elimination half-life is 6-8 hours in patients with normal renal function. Half-life is significantly prolonged (up to 80 hours) in anuria, requiring dose adjustment.
Terminal elimination half-life is 12–15 hours in adults with normal renal function; in renal impairment (CrCl <30 mL/min), half-life may extend to >30 hours, requiring dose adjustment.
Primarily renal excretion of unchanged drug via glomerular filtration; 80-90% recovered in urine within 24 hours. Biliary/fecal excretion accounts for <5%.
Renal excretion of unchanged drug accounts for approximately 60% of elimination; biliary/fecal excretion accounts for 30%; minor metabolic clearance accounts for 10%.
Category C
Category C
Tetracycline Antibiotic
Tetracycline Antibiotic